The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia

Biological Psychiatry

Volumn 49, Issue 10, 2001, Pages 861-868

  Sumiyoshi, Tomiki ^a,c   Matsui, Mie ^a   Yamashita, Ikiko ^a   Nohara, Shigeru ^a   Kurachi, Masayoshi ^a   Uehara, Takashi ^a   Sumiyoshi, Sawako ^a   Sumiyoshi, Chika ^a   Meltzer, Herbert Y ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT1A agonist; Cognitive function; Memory organization; Schizophrenia; Verbal memory; Wechsler Memory Scale Revised

Indexed keywords

BIPERIDEN; HALOPERIDOL; SEROTONIN 1A AGONIST; TANDOSPIRONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; VERBAL MEMORY;

ADULT; BASAL GANGLIA DISEASES; BRIEF PSYCHIATRIC RATING SCALE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; VERBAL BEHAVIOR; WECHSLER SCALES;

EID: 0035873389     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01025-8     Document Type: Article

References (76)

1. Assie MB, Cosi C, Koek W (1997): 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147.
2. Baker LA, Cheng LY, Amara IB (1983): The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 143:584-590.
3. Bartoszyk GD, Roos C, Ziegier H (1996): 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35:1645-1646.
4. Bengtsson HJ, Kullberg A, Millan MJ, Hjorth S (1998): The role of 5-HT1A autoreceptors and putative antipsychotic S16924. Neuropharmacology 37:349-356.
5. Buchanan RW, Holstein C, Breier A (1994): The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36:717-725.
6. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG (1990): Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16:477-499.
7. Dunn RW, Corbett R, Fielding S (1989): Effects of 5-HT1A receptor agonists and NMDA antagonists in the social interaction test and the elevated plus maze assay. Eur J Pharmacol 169:1-10.
8. Fuster JM (1980): The P refrontal Cortex, Anatomy, Physiology and Neurobiology of the Frontal Lobe. New York: Raven.
9. Gallhofer B, Bauer U, Gruppe H, Krieger S, Lis S (1996a): First episode schizophrenia: The importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 2:16S-24S.
10. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996b): Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6:S13-S20.
11. Gangarosa ME, Saykin AJ, Malamut BL, Gur RC (1988): New scoring systems for the Wechsler Memory Scale: Inter-rater reliability. J Clin Exp Neuropsychol 2:43.
12. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico FT (1991): An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11:193-197.
13. Green MF (1996): What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330.
14. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, et al (1997): Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799-804.
15. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993): Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712.
16. Hajos M, Hajos-Korcsok E, Sharp T (1999): Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 126:1741-1750.
17. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991): Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48:355-363.
18. Hertel P, Fagerquist MV, Svensson TH (1999): Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105-107.
19. Hirano H, Matsuda Y, Watanabe Y, Hirata M (1999): Further experiment regarding the role of 5-HT1A receptors in cortical acetylcholine release: Mutual interaction between 5-HT2A receptors and 5-HT1A receptors. Soc Neurosci Abstr 25(pt 1):452.
20. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al (1996): The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15:361-369.
21. Ichikawa J, O'Laughlin IA, Dai J, Fowler WL, Meltzer HY (1999): Clozapine increased extracellular acetylcholine (Achext) levels in rat medial prefrontal cortex but not striatum or nucleus accumbens in the absence of Ach-esterase inhibition. Soc Neurosci Abstr 25(pt 1):452.
22. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk SR, et al (1999): Risperidone versus haloperidol on secondary memory: Can newer medications aid learning? Schizophr Bull 25:223-232.
23. Kimura M, Sakata T, Nakagawa T, Fukumachi K, Ago Y, Tamai H, et al (1992): Clinical evaluation of tandospirone (SM-3997), on psychosomatic diseases with gastrointestinal complaints - a comparative double-blind controlled study with diazepam and placebo. Clin Eval 20:225-257.
24. Koyama T, Nakajima Y, Fujii T, Kawashima K (1999): Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Neurosci Lett 265:33-36.
25. Kuroki T, Meltzer HY, Ichikawa J (1999): Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781.
26. Lee MA, Jayathilake K, Meltzer HY (1999): A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 31:1-11.
27. Lee MA, Thompson PA, Meltzer HY (1994): Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55:82-87.
28. Lejeune F, Millan MJ (1998): Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30:172-178.
29. Levin ED, Wilson W, Rose JE, McEvoy J (1996): Nicotinehaloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429-436.
30. Mason SE, Reynolds GP (1992): Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 221:397-398.
31. Matsubara S, Meltzer HY (1989): Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45:1397-1406.
32. Medalia A, Gold J, Merriam A (1988): The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3:249-271.
33. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
34. Meltzer HY (1991a): The neurobiology of schizophrenia. Curr Opin Psychiatry 4:90-95.
35. Meltzer HY (1991b): The significance of serotonin for neuropsychiatric disorders. J Clin Psychiatry 52:70-72.
36. Meltzer HY, Matsubara S, Lee J-C (1989): Classification of typical and atypical antipsychotic drugs on the basis of dopamine-D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
37. Meltzer HY, McGurk SR (1999): The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
38. Meltzer HY, O'Laughlin IA, Dai J, Fowler WL, Ichikawa J (1999): Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (Ach-ext) levels in rat medial prefrontal cortex in the absence of Ach-esterase (AchE) inhibition. Soc Neurosci Abstr 25(pt 1):452.
39. Millan MJ, Brocco M, Gobert A, Schreider R, Dekeyne A (1999): S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 288:1002-1014.
40. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N (1999): Generalized cognitive deficits in schizophrenia: A study of first-episode patients. Arch Gen Psychiatry 56:749-754.
41. Mozley LH, Gur RC, Gur RE, Mozley PD, Alavi A (1996): Relationship between verbal memory performance and the cerebral distribution of fluorodeoxyglucose in patients with schizophrenia. Biol Psychiatry 40:443-451.
42. Murasaki M, Mori A, Endo S, Takemasa K, Hasegawa K, Kamijima K, et al (1992a): Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis - a comparative double-blind study with diazepam. Clin Eval 20:295-329.
43. Murasaki M, Mori A, Endo S, Takemasa K, Hasegawa K, Kamijima K, et al (1992b): Late phase II study of a new anxiolytic, SM-3997 (tandospirone) on neurosis. Clin Eval 20:259-293.
44. Nash JF, Meltzer HY, Gudelsky GA (1988): Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151:463-469.
45. Newberry NR, Footitt DR, Papanastassiou V, Reynolds D (1999): Actions of 5-HT on human neocortical neurones in vitro. Brain Res 833:93-100.
46. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ (1996): Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35:119-121.
47. 35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256.
48. Parada MA, Hernandez L, Puig de Parada M, Rada P, Murzi E (1997): Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J Pharmacol Exp Ther 281:582-588.
49. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, et al (2000): Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249-258.
50. Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994): 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18:218-224.
51. Rhoades HM, Overall JE (1988): The semistructured BPRS interview and rating guide. Psychopharmacol Bull 10:101-104.
52. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997): Clozapine increases dopamine in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338:R3-R5.
53. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, et al (1997): Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study. Acta Psychiatr Scand 95:40-43.
54. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al (1991): Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624.
55. Sharma T (1999): Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 174:44-51.
56. Sharma T, Mockler D (1998): The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18:12S-19S.
57. Shimizu H, Hirose A, Tatsuno T, Nakamura M, Katsube J (1987): Pharmacological properties of SM-3997: A new anxioselective anxiolytic candidate. Jpn J Pharmacol 45:493-500.
58. Shimizu H, Karai N, Hiroe A (1988): Interaction of SM-3997 with serotonin receptors in brain. Jpn J Pharmacol 46:311-314.
59. Shimizu H, Tatsuno T, Tanaka H, Hirose A, Araki Y, Nakamura M (1992): Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 59:105-112.
60. Simpson GM, Angus JW (1970): A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
61. Spohn HE, Strauss ME (1989): Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367-380.
62. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993): Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384.
63. Sugishita M (in press): The Japanese Version of the Wechsler Memory Scaled-Revised. Tokyo: Nihon Bunka Kagakusya.
64. Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et al (1993): Time course of dopamine-D2 and serotonin-5-HT2 receptor occupancy rates by haloperidol and clozapine in vivo. Jpn J Psychiatr Neurol 47:131-137.
65. Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et al (1994a): In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47:553-557.
66. Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et al (1994b): Time course of dopaminel,2 and serotonin2 receptor binding of antipsychotics in vivo. Pharmacol Biochem Behav 49:165-169.
67. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996): Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708:209-214.
68. Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, et al (1995): Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology 12:57-64.
69. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000): Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia (letter). J Clin Psychopharmacol 20:386-388.
70. 3H]tandospirone binding sites in the rat brain. Brain Res 546:181-189.
71. Tanda G, Carboni E, Frau R, Di CG (1994): Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115:285-288.
72. Volonte M, Cerutti M, Fodritto F, Monferini F, Borsin F (1997): BIMG, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 69:182-190.
73. Wadenberg ML, Ahlenius S (1991): Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53.
74. Wadenberg ML, Cortizo L, Ahlenius S (1994): Evidence for specific interactions between 5-HT1A and dopamine-D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47:509-513.
75. Wechsler D (1987): WMS-R, Wechsler Memory Scale-Revised Manual. New York: Harcourt Brace Jovanovich.
76. Wieland S, Fischette CT, Lucki I (1993): Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 32:561-573.